The Government of South Africa and President Cyril Ramaphosa were applauded by the World Health Organization (WHO) for the launch of the national rollout of lenacapavir (LEN), a groundbreaking long-acting HIV prevention injection that marks a major milestone in the country’s efforts to reduce new HIV infections and move closer to ending HIV. Launched in Secunda, Mpumalanga province on 5 June 2026 the introduction of the twice-yearly injectable pre-exposure prophylaxis (PrEP) option marks South Africa’s on – going efforts and commitment to expand access to effective, people-centred prevention options.
For INERELA+ LEN, the first twice-yearly injectable PrEP product offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. With just two doses per year, LEN is a transformative step forward in protecting people at risk of HIV – particularly those who face challenges with daily adherence, stigma, or access to health care.
The roll out in South Africa highlights the collaboration between the government, civil society, private sector and development partners and donors including the Global Fund who are committed to ending HIV as a public health threat. South Africa is among the first countries to move from policy to implementation receiving early supply, updating its essential medicines list, and preparing health systems for rollout. This demonstrates what is possible when governments, communities and partners work together with a clear purpose.
South Africa has long been a global leader in the HIV response, driven by strong political commitment, scientific excellence and community partnerships. The rollout of lenacapavir builds on decades of progress and reflects the country’s determination to ensure that new prevention technologies reach those who need them most. By introducing this highly effective prevention tool into public health programmes, South Africa joins the other early adopter countries seeking to accelerate progress towards ending HIV and reducing health inequities.